Dr. Philip Zhou Stock Investing

This is a guest post by Internal_Ad_1091. Listen up! Im about to present a once-in-a-generation opportunity to 75x your money**.** Too much, or too good to be true? Im being conservative. Hear me out. First, I shall Flex: I am an MD and a Professor. To spell out the obvious, I have insight into what matters in the medical world. Many pure researchers lack this (cough cough Elisabeth Bik). In addition, As medical school faculty, If I can't figure it out, I know who to ask. I started investing (profitably) before most of you were born. Why flex? To make it abundantly clear, my opinion on biotech investing matters just a little. With that said, once more, listen up! The Pickle: You youngins haven't noticed, but Alzheimer's is the 6th leading cause of death in the US. Currently, Alzheimer's is an epidemic. The kicker is, there is NO effective treatment. The FDA needed a drug so desperately they approved Aduhelm. This drug has significant adverse events. The ri...

SAVA stock has been unfairly beat down recently and we should step back and take a look at the bigger picture. I did drug development for Pfizer and I'm a neurologist who has treated tens of thousands of Alzheimer's patients, so I can discuss any aspect of the science. I can tell you that research papers are typically full of errors, and end up being published in big journals without anyone ever noticing. The errors don't imply fraud itself. These western blots from 15 years ago was before simufilam was even discovered. The western blots are done on a plate, which is all analog. To make it digital in the early 2000s, you had to piece it together manually in photoshop. Some old Chinese scientist may not be the best at this sort of work. The discovery of simufilam makes logical sense. Previous research done by others found excessive tau hyperphosphorylation in many neurodegenerative diseases including Alzheimer's. And they found a link between tau hyperphosp...

  Buying shares of early stage biotech companies is one of the ways that cash-strapped investors can plant the seeds of massive growth. These companies have the potential to be 100x or 1000x the initial investment. What better way than to look into a cure for Alzheimer’s? I got into SAVA (Cassava Biosciences, lead drug simufilam) at $47 when I was reading an article on Seeking Alpha about the promising company. Given my background treating Alzheimer’s patients, I knew I could do my own homework on the data. They have groundbreaking 9 month data on their new Alzheimer's drug, far better than any drug before it. At 9 months, instead of a 4 point decline as is typical in disease progression, it's a 3 point improvement. This 7 point difference is a very big deal for both cognition and ability to live independently. If even results half this good are replicated in a Phase 3 trial, the FDA would approve it easily. For me, seeing the data, the stock is already de-risked. The stock is ...